Skip to main navigation Skip to search Skip to main content

Effectiveness and safety of daclizumab beta versus intramuscular interferon beta-1a in patents previously treated with glatiramer acetate: Subgroup analysis from the DECIDE study

Research output: Other contribution

Original languageUndefined/Unknown
StatePublished - Jan 1 2018

Publication series

NameProvidence Neuroscience Institute Research

Cite this